文献速递类风湿关节炎系统性红斑狼疮其他结缔组织病

系统性自身免疫性风湿病患者对SARS-CoV-2疫苗接种的反应取决于免疫抑制方案:一项配对的前瞻性队列研究

Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study.
PubMed 文献 · Ann Rheum Dis · 2022-03-18

该配对前瞻性队列研究纳入82例系统性自身免疫性风湿病(SARD)患者与82例年龄性别匹配的健康对照(HC),评估两剂mRNA疫苗接种后的体液反应。SARD患者首剂后血清转换率(SCR)低于HC(65% vs 100%,p<0.0001),第二剂后趋近(94% vs 100%);第二剂后联合DMARD治疗者SCR低于其他组(81% vs 单药治疗95%,p=0.01;vs 无DMARD治疗及HC均为100%,均p<0.0001)。作者结论认为SARD患者第二剂mRNA疫苗后反应良好,但免疫抑制药物选择及免疫调节治疗种类数明显影响SCR和总体抗体水平。

要点

  • SARD患者首剂mRNA疫苗后SCR为65%,低于HC的100%(p<0.0001),第二剂后为94% vs 100%。
  • 第二剂后联合DMARD治疗者SCR为81%,低于单药治疗95%(p=0.01)及无DMARD治疗和HC的100%(均p<0.0001)。
  • 两剂后SARD患者抗体水平均低于HC,接种反应主要由DMARD和/或糖皮质激素种类数决定,联合治疗者反应最差。

核心结论

  • SARD患者接种第二剂mRNA疫苗后反应良好,但免疫抑制药物选择对SCR和总体抗体水平有明显影响,不同免疫调节治疗种类数决定接种反应。

研究设计与样本

  • 配对前瞻性队列研究,纳入82例SARD患者,按性别和年龄1:1匹配82例健康对照(HC)。
  • 评估两组间两剂mRNA疫苗体液反应(SCR和SARS-CoV-2抗体水平)差异及SARD患者内治疗的影响。

主要发现

  • 首剂后SCR在患者组低于HC(65% vs 100%,p<0.0001),第二剂后趋近(94% vs 100%)。
  • 第二剂后联合DMARD治疗者SCR为81%,低于单药治疗95%(p=0.01),也低于无DMARD治疗和HC的100%(均p<0.0001)。
  • 两剂后抗体水平在患者组均低于HC。
  • 接种反应主要由DMARD和/或糖皮质激素种类数决定,接受联合治疗(二联和三联)者反应最差。

关键数值与推荐

  • 首剂后SCR:SARD患者65% vs HC 100%(p<0.0001)。
  • 第二剂后SCR:SARD患者94% vs HC 100%。
  • 第二剂后联合DMARD治疗者SCR 81% vs 单药治疗95%(p=0.01);vs 无DMARD治疗100%(p<0.0001);vs HC 100%(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the humoral response to messenger RNA (mRNA) vaccine of patients with systemic autoimmune rheumatic disease (SARD) and the effect of immunosuppressive medication in a matched cohort study. METHODS: Patients with SARD were enrolled and matched 1:1 for sex and age with healthy control (HC) subjects. Differences in humoral response to two doses of an mRNA vaccine in terms of seroconversion rate (SCR) and SARS-CoV-2 antibody level between the two groups and the impact of treatment within patients with SARD were assessed. RESULTS: We enrolled 82 patients with SARD and 82 matched HC. SCR after the first dose was lower among the patient group than that of HC (65% compared with 100% in HC, p<0.0001) but levelled up after the second dose (94% vs 100%). After the second dose, SCR was lower for patients on combination disease-modifying antirheumatic drug (DMARD) therapy compared with all other groups (81% compared with 95% for monotherapy, p=0.01; 100% for both no DMARD therapy and HC, both p<0.0001). In addition, antibody levels after both doses were lower in patients compared with HC. We found that vaccination response was determined primarily by the number of DMARDs and/or glucocorticoids received, with patients receiving combination therapy (dual and triple therapy) showing the poorest response. CONCLUSIONS: Patients with SARD showed a good response after the second vaccination with an mRNA vaccine. However, the choice of immunosuppressive medication has a marked effect on both SCR and overall antibody level, and the number of different immunomodulatory therapies determines vaccination response.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mandl P, Tobudic S, Haslacher H, et al. Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study. Ann Rheum Dis. 2022. PMID: 35304407. doi:10.1136/annrheumdis-2021-221788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。